CYCLACEL PHARMACEUTICALS INC (CYCC) Stock Price & Overview
NASDAQ:CYCC • US23254L8019
The current stock price of CYCC is 6.365 USD. Today CYCC is down by -5.98%. In the past month the price decreased by -28.48%. In the past year, price decreased by -97.37%.
CYCC Key Statistics
- Market Cap
- 14.258M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -122.02
- Dividend Yield
- N/A
CYCC Stock Performance
CYCC Stock Chart
CYCC Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CYCC. When comparing the yearly performance of all stocks, CYCC is a bad performer in the overall market: 96.83% of all stocks are doing better.
CYCC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CYCC. While CYCC seems to be doing ok healthwise, there are quite some concerns on its profitability.
CYCC Earnings
CYCC Forecast & Estimates
For the next year, analysts expect an EPS growth of 39.49% and a revenue growth 88.68% for CYCC
CYCC Groups
Sector & Classification
CYCC Financial Highlights
Over the last trailing twelve months CYCC reported a non-GAAP Earnings per Share(EPS) of -122.02. The EPS increased by 96.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -146.06% | ||
| ROE | -177.03% | ||
| Debt/Equity | 0 |
CYCC Ownership
CYCC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.14 | 413.319B | ||
| AMGN | AMGEN INC | 16.78 | 203.007B | ||
| GILD | GILEAD SCIENCES INC | 16.53 | 183.41B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.35 | 120.332B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.76 | 81.051B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.29 | 42.097B | ||
| INSM | INSMED INC | N/A | 31.351B | ||
| NTRA | NATERA INC | N/A | 29.344B | ||
| BIIB | BIOGEN INC | 12.25 | 27.007B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.42 | 21.856B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.914B | ||
| EXAS | EXACT SCIENCES CORP | 308.96 | 19.724B | ||
| MRNA | MODERNA INC | N/A | 19.468B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CYCC
Company Profile
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company is headquartered in Berkeley Heights, New Jersey. The firm is focused on developing cancer medicines based on cell cycle, epigenetics and mitosis biology. Its epigenetic/anti-mitotic program is evaluating plogo, a Polo-like kinase 1 (PLK1) inhibitor, in solid tumors and hematological malignancies. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle, and is a regulator of the DNA damage checkpoint. The Company’s plogo is a novel, small-molecule, selective and potent PLK1 inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogo in solid tumor and hematological malignancy indications. PLK1 over-expressing tumors include colorectal, esophageal, gastric, leukemia, lung, lymphoma, ovarian and squamous cell cancers.
Company Info
CYCLACEL PHARMACEUTICALS INC
200 Connell Dr Ste 1500
Berkeley Heights NEW JERSEY 07922 US
CEO: Spiro Rombotis
Employees: 12
Phone: 19085177330
CYCLACEL PHARMACEUTICALS INC / CYCC FAQ
What does CYCC do?
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company is headquartered in Berkeley Heights, New Jersey. The firm is focused on developing cancer medicines based on cell cycle, epigenetics and mitosis biology. Its epigenetic/anti-mitotic program is evaluating plogo, a Polo-like kinase 1 (PLK1) inhibitor, in solid tumors and hematological malignancies. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle, and is a regulator of the DNA damage checkpoint. The Company’s plogo is a novel, small-molecule, selective and potent PLK1 inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogo in solid tumor and hematological malignancy indications. PLK1 over-expressing tumors include colorectal, esophageal, gastric, leukemia, lung, lymphoma, ovarian and squamous cell cancers.
What is the current price of CYCC stock?
The current stock price of CYCC is 6.365 USD. The price decreased by -5.98% in the last trading session.
Does CYCLACEL PHARMACEUTICALS INC pay dividends?
CYCC does not pay a dividend.
How is the ChartMill rating for CYCLACEL PHARMACEUTICALS INC?
CYCC has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is CYCC stock listed?
CYCC stock is listed on the Nasdaq exchange.
What is the expected growth for CYCC stock?
The Revenue of CYCLACEL PHARMACEUTICALS INC (CYCC) is expected to grow by 88.68% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.